A Korean research team has built a small implantable chip that can wirelessly track changes in acetylcholine, a neurotransmitter involved in memory and learning, inside the brain of a living animal. In miniature pigs, the team saw the acetylcholine signal rise after they gave donepezil, an Alzheimer's medication, and then slowly drop back toward its starting level. The work was led by Professor Kyung-In Jang of KAIST's Department of Mechanical Engineering, with collaborators from DGIST, the Korea Brain Research Institute, and the Korea Research Institute of Bioscience and Biotechnology. The findings were published October 14 in the Cell Press journal Device.
Donepezil works by blocking acetylcholinesterase, the enzyme that breaks acetylcholine down, so the neurotransmitter stays active longer. Being able to watch that effect unfold in a specific brain region, the prefrontal cortex in this case, gives researchers a way to see how a drug actually behaves in the brain rather than inferring it from outside measures.
The sensor combines porous chitosan, which offers a large surface for attaching the enzymes that detect acetylcholine, with ultrathin silver-platinum nanowires that turn the hydrogen peroxide produced by the enzymatic reaction into an electrical signal. To cut down on interference from other molecules, the probe pairs an enzyme-coated electrode with an uncoated one and compares the two readings. The data are processed by a miniaturized circuit and sent to an external device by Bluetooth. The chip can also stimulate nerve cells with light from an integrated micro-LED, and in a separate experiment in transgenic mice the team showed that light stimulation raised acetylcholine signals.
The authors say the platform could help compare neurotransmitter responses across different drug doses and dosing intervals, and that it lays groundwork for closed-loop systems that adjust stimulation based on the brain's measured response. The study itself, however, measured chemistry in animal brains and did not show any therapeutic effect on Alzheimer's disease or any memory improvement. The researchers note that long-term safety and the stability of measurements after implantation still need to be validated before the technology could be used in people. The team plans to commercialize it through N-Side Inc., a faculty-founded startup.